Valuation: OLIPASS Corporation

Market Cap 26.53B 18.57M 16.13M 14.98M 13.82M 26.03M 1.77B 26.5M 177M 69.44M 881M 69.75M 68.22M 2.96B P/E 2021
-10.8x
P/E 2022 -7.66x
Enterprise Value 20.34B 14.24M 12.37M 11.48M 10.59M 19.95M 1.36B 20.31M 136M 53.23M 675M 53.46M 52.29M 2.27B EV / Sales 2021
295x
EV / Sales 2022 79x
Free-Float
48.85%
Yield 2021 *
-
Yield 2022 -
3 years 1,568
Extreme 1568
34,500
5 years 1,568
Extreme 1568
158,000
10 years 1,568
Extreme 1568
240,666.67
Manager TitleAgeSince
Chief Executive Officer 54 2025-05-21
Corporate Officer/Principal 34 2024-11-27
Comptroller/Controller/Auditor 67 2025-03-30
Director TitleAgeSince
Director/Board Member 54 2024-11-27
Director/Board Member 34 2024-11-27
Director/Board Member 66 -
Change 5-day change 1-year change 3-year change Capi.($)
-13.92%-.--%-.--%-90.11% 9.28M
-3.74%-1.56%+45.14%+64.45% 55.2B
-0.81%-0.33%+27.15%+81.12% 55.6B
-0.11%+0.86%-15.63%-14.71% 23.51B
-1.58%-5.51%-3.51%+359.44% 22.35B
-4.01%-2.68%+12.50%-12.70% 20.6B
-1.23%-3.51%+25.70%-31.88% 17.45B
-3.34%-6.96%+22.02%+515.48% 15.16B
+1.16%+0.58%+51.87%+183.97% 13.91B
-5.09%-13.14%+151.85%+272.20% 13.74B
Average -3.27%-5.98%+31.71%+132.73% 23.75B
Weighted average by Cap. -2.10%-0.46%+31.17%+122.31%

Financials

2021 2022
Net sales 852M 596K 518K 481K 444K 836K 56.93M 851K 5.69M 2.23M 28.27M 2.24M 2.19M 95.08M 2.3B 1.61M 1.4M 1.3M 1.2M 2.25M 153M 2.29M 15.35M 6.01M 76.21M 6.04M 5.9M 256M
Net income -25.13B -17.6M -15.28M -14.19M -13.09M -24.66M -1.68B -25.1M -168M -65.79M -834M -66.08M -64.63M -2.81B -24.17B -16.92M -14.7M -13.65M -12.59M -23.71M -1.62B -24.14M -162M -63.26M -802M -63.54M -62.15M -2.7B
Net Debt -18.29B -12.8M -11.12M -10.33M -9.53M -17.94M -1.22B -18.27M -122M -47.87M -607M -48.08M -47.03M -2.04B -6.2B -4.34M -3.77M -3.5M -3.23M -6.08M -414M -6.19M -41.41M -16.22M -206M -16.29M -15.93M -692M
Logo OLIPASS Corporation
OliPass Corp is a Korea-based company principally engaged in the research and development of biopharmaceuticals. The Company is mainly engaged in the development of non-opioid analgesics, amyotrophic lateral sclerosis (ALS) treatments, therapies for age-related macular degeneration, and diabetic retinopathy. In addition, the Company researches, develops and sells functional cosmetics through artificial gene platform technology.
Employees
78
  1. Stock Market
  2. Stocks
  3. A244460 Stock